Doxofylline: A new generation xanthine bronchodilator devoid of major cardiovascular adverse effects

Current Medical Research and Opinion

Volumn 16, Issue 4, 2001, Pages 258-268

  Dini, F L ^a   Cogo, R ^b  

^a Villamarina Hospital   (Italy)

^b Ospedale Zappatoni   (Italy)

Author keywords

Arrhythmogenic; Asthma; Bronchodilators; Chronic obstructive pulmonary disease; Doxofylline; Theophylline

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; AMINOPHYLLINE; BAMIFYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DIGITALIS; DOXOFYLLINE; ENPROFYLLINE; METHYLXANTHINE; THEOPHYLLINE; XANTHINE DERIVATIVE;

ADRENERGIC STIMULATION; ARTICLE; ASTHMA; CARDIOVASCULAR EFFECT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG SAFETY; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; SINUS TACHYCARDIA;

ANIMALS; ARRHYTHMIA; ASTHMA; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; DRUG EVALUATION, PRECLINICAL; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PHOSPHODIESTERASE INHIBITORS; PULMONARY HEART DISEASE; RECEPTORS, PURINERGIC P1; RISK FACTORS; SAFETY; THEOPHYLLINE; TREATMENT OUTCOME; XANTHINES;

EID: 0035101284     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079901750120196     Document Type: Article

References (58)

1. Bronchodilator therapy in chronic obstructive pulmonary disease
2. Theophylline in the management of asthma: Time for reappraisal?
3. Cor pulmonale
4. Arrhythmogenicity of theophylline: A multivariate analysis of clinical determinants
5. Cardiac arrhythmias in hospitalized patients with chronic obstructive pulmonary disease
6. Repetitive, monomorphic ventricular tachycardia: Clinical and electrophysiological characteristics in patients with or without organic heart disease
7. Cardiac arrhythmias caused by nebulized beta-agonist therapy
8. Betaagonists. Friends or foes?
9. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
10. Infrequent cardiac deaths occur in bronchial asthma
11. Effect of high-dose salbutamol on cardiac rhythm in severe chronic airflow obstruction: A controlled study
12. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment
13. The use of beta-agonists and the risk of death or near death from asthma
14. Sudden cardiac death in bronchial asthma, and inhaled β-adrenergic agents
15. Bronchodilators and acute cardiac death
16. Pulse rate, coronary heart disease and death: The NHANES I epidemilogical follow-up study
17. Heart rate and cardiovascular mortality: The Framingham Study
18. Heart rate, a risk factor for cardiovascular mortality in elderly men
19. Cardiovascular death and left ventricular remodelling two years after myocardial infarction. Baseline predictors and impact of long term use of captopril: Information from the survival and ventricular enlargement (SAVE) trial
20. Beta-adrenergic stimulation causes cardiocyte apoptosis: Influence of tachycardia and hypertrophy
21. Beta-blockers: Heart rate reduction as a mechanism of benefit
22. Noninvasive assessment of chronotropic and inotropic response to preferential β1 and β2 adrenoreceptor stimulation
23. Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: In vivo and in vitro evidence of enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death
24. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts
25. A randomized trial of propanolol in patients with acute myocardial infarction. I. Mortality results
26. Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction
27. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
28. Beta-blockade during and after myocardial infarction: An overview of the randomised trials
29. Beta-blockers in heart failure: The evidence from clinical trials
30. Adenosine and adenine nucleotide action on cardiac cellular excitation
31. Cardiovascular response to increasing theophylline concentrations
32. Aminophylline induced atrial fibrillation
33. Cardiac arrhythmias as a result of intravenous infusion of theophylline in patients with airway obstruction
34. Toxicity form IV aminophylline infusion in critical ill patients
35. Atrial arrhythmias exacerbated by theophylline. Response to verapamil and evidence for triggered activity in man
36. Caffeine and theophylline as adenosine receptor antagonists in humans
37. Universal adenosine receptor antagonism is neither necessary nor desirable with xanthine antiasthmatic
38. The profile of action of enprophylline, or why adenosine antagonism seems less desirable with xanthine antiasthmatic
39. Electrophysiologic effects of theophylline in young patients with recurrent symptomatic bradyarrhythmias
40. Doxofylline and theophylline are xanthines with partly different mechanisms of action in animals
41. Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors
42. Doxofylline, an adenosine nonblocking xanthine, does not induce cardiostimulants effects
43. A1- and A2selective adenosine antagonists: In vivo characterisation of cardiovascular effects
44. Effetti sul sistema cardio-respiratorio indotti dalla doxofillina
45. Chronotropic and arrhythmogenic effects of two methylxanthine bronchodilators, doxofylline and theophylline, evaluated by Holter monitoring
46. Alterazioni del ritmo cardiaco in pazienti con broncopneumopatia cronica ostruttiva
47. Treatment with xanthine derivative, doxofylline, in patients intollerant to theophylline
48. Studio clinico controllato doxofillina versus aminofillina nel trattamento delle sindromi da insufficienza acuta cardiorespiratoria
49. Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: A double-blind, randomized, multicentre trial
50. Doxofylline compared to theophylline in chronic reversible asthma. A double-blind placebo-controlled study
51. Oral doxofylline in patients with chronic obstructive pulmonary disease
52. Pulmonary function tests in patients with congestive heart failure
53. Pulmonary factors limiting exercise capacity in patients with heart failure
54. Atrial natriuretic peptide and bronchial hyperresponsiveness in patients with mitral stenosis
55. Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure
56. Pulmonary function tests in patients with chronic heart failure and chronic airway obstruction. Effects of doxofylline
57. Oral administered methylxanthines improve gas exchange and exercise tolerance in patients with chronic hypoxaemic heart failure
58. Methylxanthine drug therapy in chronic heart failure associated with hypoxaemia: Double-blind placebo controlled clinical trial of doxofylline versus theophylline and bamifylline